Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 251-394-8 | CAS number: 33145-10-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 4 April 2016 to 15 April 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 016
- Report date:
- 2016
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- (1987)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: JMAFF Guidelines (2000), including the most recent revisions.
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- 2,2'-(2-methylpropylidene)bis[4,6-xylenol]
- EC Number:
- 251-394-8
- EC Name:
- 2,2'-(2-methylpropylidene)bis[4,6-xylenol]
- Cas Number:
- 33145-10-7
- Molecular formula:
- C20H26O2
- IUPAC Name:
- 2-[1-(2-hydroxy-3,5-dimethylphenyl)-2-methylpropyl]-4,6-dimethylphenol
- Test material form:
- solid: particulate/powder
- Remarks:
- migrated information: powder
- Details on test material:
- Identification: Lowinox® 22IB46IUPAC: 2,2’-(2-methylpropylidene)bis[4,6-xylenol]Appearance: White to cream coloured powderBatch: WB44L0016Purity/Composition: 99.7%Test item storage: At room temperatureStable under storage conditions until: 18 November 2018 (retest date)
Constituent 1
- Specific details on test material used for the study:
- Chemical name (IUPAC), synonym or trade name2,2’-(2-methylpropylidene)bis[4,6-xylenol]CAS Number33145-10-7pH (1% in water, indicative range)8.0 – 7.2 (determined by WIL Research Europe)
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:WI (Han) (outbred, SPF-Quality).
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Species: Rat, Wistar strain, Crl:WI (Han) (outbred, SPF-Quality). Recognized by international guidelines as the recommended test system (e.g. OECD, EC).
Source: Charles River Deutschland, Sulzfeld, Germany.
Number of animals: 5 males and 5 females (females were nulliparous and non-pregnant).
Age and body weight: Young adult animals (approx. 10 weeks old) were selected. Body weight variation did not exceed +/- 20% of the sex mean.
Identification: Tail mark with indelible ink.
Health inspection: At least prior to dosing. It was ensured that the animals were healthy and that the skin to be treated was intact and free from any abnormality.
Animal Husbandry
Conditions: Environmental controls for the animal room were set to maintain 18 to 24°C, a relative humidity of 40 to 70%, at least 10 air changes/hour, and a 12-hour light/12-hour dark cycle: the photoperiod was between 07:00 and 19:00 hrs daily. Any variations to these conditions were maintained in the raw data and had no effect on the outcome of the study.
Accommodation: Individually housed in labeled Makrolon cages (MIII type, height 18 cm.) containing sterilized sawdust as bedding material (Lignocel S 8-15, JRS - J.Rettenmaier & Söhne GmbH +CO. KG, Rosenberg, Germany) and paper as cage-enrichment (Enviro-dri, Wm. Lillico &Son (Wonham Mill Ltd), Surrey, United Kingdom).
Acclimatization period was at least 5 days before start of treatment under laboratory conditions. During the acclimatization period the animals were group housed in Makroloncages (MIV type, height 18 cm).
Diet: Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany).
Water: Free access to tap water.
Diet, water, bedding and cage enrichment evaluation for contaminants and/or nutrients was performed according to facility standard procedures. There were no findings that could interfere with the study.
Administration / exposure
- Type of coverage:
- occlusive
- Vehicle:
- propylene glycol
- Details on dermal exposure:
- Method: Dermal application.
The test item (preparation) was stirred on a magnetic stirrer during application.
Clipping: One day before exposure (Day -1) an area of approximately 5x7 cm on the back of the animal was clipped with a clipper (Moser Genio plus, standard blade (0.7 mm).
Application: The preparation was applied on an area of approx. 10% of the total body surface, i.e. approx. 25 cm² for males and 18 cm² for females. The preparation was held in contact with the skin with a dressing, consisting of a surgical gauze patch (Surgy 1D)*, successively covered with aluminum foil and Coban elastic bandage*. A piece of Micropore tape* was additionally used for fixation of the bandages in females only.*. Manufacturers: Laboratoires Stella s.a., Liege, Belgium (surgical gauze) and 3M, St. Paul, Minnesota, U.S.A. (Coban & Micropore).
Frequency: Single dosage, on Day 1.
Dose level (volume): 2000 mg/kg (10 mL/kg) body weight.
Application period: 24 hours, after which dressings were removed and the skin cleaned of residual test item by gentle washing using tap water. - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg (10 mL/kg) body weight.
- No. of animals per sex per dose:
- 5 females and 5 males (10 animals total) administered a single dose of 2000 mg/kg (10 mL/kg) body weight on day 1.
- Control animals:
- not specified
- Details on study design:
- Test Item Preparation
Vehicle: Propylene glycol (Merck, Darmstadt, Germany) (specific gravity 1.036) Rationale: The vehicle was selected based on trial preparation performed at WIL Research Europe and on test item data supplied by the Sponsor. There was no information available regarding the solubility or stability in vehicle.
Preparation: The preparation (w/w) were kept at room temperature and dosed within 4 hours after adding the vehicle to the test item. Homogeneity was assessed by visual inspection of the solutions and the formulations were stirred during dosing, which ensures homogeneity sufficient for these kinds of studies. Adjustment was made for specific gravity of the vehicle. No correction was made for purity of the test item.
Observations
Mortality/Viability: Twice daily.
Body weights: Days 1 (pre-administration), 8 and 15 and at death (if found dead or sacrificed after Day 1).
Clinical signs: At periodic intervals on the day of dosing (Day 1) and once daily thereafter, until Day 15. The time of onset, degree and duration were recorded and the symptoms graded according to fixed scales: Maximum grade 4: grading slight (1) to very severe (4) Maximum grade 3: grading slight (1) to severe (3) Maximum grade 1: presence is scored (1).
Necropsy: The moribund animal and those surviving to the end of the observation period were sacrificed by an oxygen/carbon dioxide (40% / 60%) inhalation procedure. All animals assigned to the study were subjected to necropsy and descriptions of all internal macroscopic abnormalities recorded.
Evaluation: A dermal LD50 value was derived. The results were evaluated according to: -Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments);-Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of items and mixtures (including all amendments).. - Statistics:
- Statistical analysis was not conducted.
Results and discussion
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- One female animal was sacrificed for humane reasons on Day 3. No further mortality occurred.
- Clinical signs:
- Lethargy, tremors, flat- and hunched posture, lateral recumbency, rales, uncoordinated movements, shallow respiration, piloerection, chromodacryorrhoea (snout), hypersensitivity to touch and/or ptosis were noted for the animals of both sexes.
The male animals had recovered from the symptoms by Day 4 and the females by Day 6. Additionally, one female animal showed lean appearance between Days 5 and 10.
General erythema, erythema maculate and/or scabs were seen in the skin-area of the animals during the observation period. These local effects were considered not to have affected the conclusion of the study. - Body weight:
- The changes noted in body weight gain in males were within the range expected for rats used in this type of study and were therefore considered not indicative of toxicity.
The female animals showed body weight loss or reduced body weight gain between Days 1 and 8. At Day 15 the body weight of the animals were within the expected rage again. - Gross pathology:
- No abnormalities were found at macroscopic post mortem examination of the animals.
- Other findings:
- No other findings were specified.
Any other information on results incl. tables
Mortality Data
Test day |
1 |
1 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
Hours after treatment |
0 |
2 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Males 2000 MG/KG |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Females 2000 MG/KG |
- |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Clinical signs
Test day |
|
1 |
1 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
Hours after treatment |
Max grade |
0 |
2 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Males 2000 MG/KG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANIMAL 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Behaviour |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lethargy |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Spasms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tremor (General) |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Flat posture |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shallow Respiration |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (Snout) |
(3) |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hypersensitivity to touch |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Ptosis |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spams |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tremor (General) |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Gait/motility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Uncoordinated movements |
(3) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shallow respiration |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Erythema maculate (treated skin) |
(4) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Secrretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (snout) |
(3) |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hypersensitivity to touch |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Ptosis |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spams |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tremor (General) |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Gait/motility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Uncoordinated movements |
(3) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shallow respiration |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Erythema (Treated skin) |
(4) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Scabs (shoulder right) |
(3) |
- |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (Snout) |
(3) |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hypersensitivity to touch |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Ptosis |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spasms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tremor (General) |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Gait/motility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Uncoordinated movements |
(3) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shallow respiration |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (Snout) |
(3) |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hypersensitivity to touch |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Behaviour |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lethargy |
(3) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Spasms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tremor (General) |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Gait/motility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Uncoordinated movements |
(3) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quick breathing |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (snout) |
(3) |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hypersensitivity to touch |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Ptosis |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
FEMALES 2000 MG/KG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ANIMAL 6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Behaviour |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lethargy |
(3) |
- |
- |
- |
1 |
2 |
2 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Spasms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tremor (General) |
(3) |
- |
- |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Flat posture |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Gait/motility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Uncoordinated movements |
(3) |
- |
- |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shallow respiration |
(3) |
- |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (snout) |
(3) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lean |
(1) |
- |
- |
- |
- |
- |
- |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
Hypersensitivity to touch |
(1) |
- |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Ptosis |
(3) |
- |
- |
1 |
1 |
2 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Hypothermia |
(1) |
- |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Behaviour |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lethargy |
(3) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Spasms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tremor (General) |
(3) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Flat posture |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Gait/motility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Uncoordinated movements |
(3) |
- |
- |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shallow respiration |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hypersensitivity to touch |
(1) |
- |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Ptosis |
(3) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Behaviour |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lethargy |
(3) |
- |
- |
- |
2 |
3 |
|
|
|
|
|
|
|
|
|
|
|
|
Spasms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tremor (General) |
(3) |
- |
- |
- |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Flat posture |
(1) |
- |
- |
- |
1 |
- |
|
|
|
|
|
|
|
|
|
|
|
|
Lateral recumbency |
(1) |
- |
- |
- |
- |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
- |
1 |
- |
|
|
|
|
|
|
|
|
|
|
|
|
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rales |
(3) |
- |
- |
- |
1 |
2 |
|
|
|
|
|
|
|
|
|
|
|
|
Shallow respiration |
(3) |
- |
- |
- |
1 |
2 |
|
|
|
|
|
|
|
|
|
|
|
|
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (treated skin) |
(4) |
- |
- |
- |
1 |
2 |
|
|
|
|
|
|
|
|
|
|
|
|
Piloerection |
(1) |
- |
- |
- |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (snout) |
(3) |
- |
1 |
1 |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hypersensitivity to touch |
(1) |
- |
- |
- |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Ptosis |
(3) |
- |
- |
- |
1 |
2 |
|
|
|
|
|
|
|
|
|
|
|
|
Hypothermia |
(1) |
- |
- |
- |
- |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
ANIMAL 9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Behaviour |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lethargy |
(3) |
- |
- |
- |
2 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Spasms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tremor (general) |
(3) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Flat posture |
(1) |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Hunched posture |
(1) |
- |
- |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Gait/motility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Uncoordinated movements |
(3) |
- |
- |
- |
- |
- |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shallow respiration |
(3) |
- |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Piloerection |
(1) |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (Snout) |
(3) |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hypersensitivity to touch |
(1) |
- |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Ptosis |
(3) |
- |
- |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Behaviour |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lethargy |
(3) |
- |
- |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Spasms |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tremor (general) |
(3) |
- |
- |
- |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Posture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hunched posture |
(1) |
- |
- |
1 |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Gait/motility |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Uncoordinated movements |
(3) |
- |
- |
- |
1 |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
Breathing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shallow respiration |
(3) |
- |
- |
- |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Skin/fur |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General erythema (Treated skin) |
(4) |
- |
- |
- |
1 |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
Piloerection |
(1) |
- |
- |
1 |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Secretion/excretion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chromodacryorrhoea (Snout) |
(3) |
- |
1 |
2 |
2 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
Various |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hypersensitivity to touch |
(1) |
- |
- |
- |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Ptosis |
(3) |
- |
- |
1 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
‘-‘ = Sign not observed
Body weights (gram)
SEX/DOSE LEVEL |
ANIMAL |
DAY 1 |
DAY 8 |
DAY 15 |
MALES 2000 MG/KG |
|
|
|
|
|
1 |
282 |
292 |
317 |
|
2 |
286 |
303 |
340 |
|
3 |
276 |
285 |
313 |
|
4 |
276 |
287 |
316 |
|
5 |
273 |
292 |
316 |
|
MEAN |
279 |
292 |
320 |
|
ST. DEV. |
5 |
7 |
11 |
|
N |
5 |
5 |
5 |
FEMALES 2000 MG/KG |
|
|
|
|
|
6 |
186 |
180 |
194 |
|
7 |
189 |
188 |
193 |
|
8 |
185* |
--- |
-- |
|
9 |
188 |
191 |
211 |
|
10 |
191 |
193 |
200 |
|
MEAN |
188 |
188 |
200 |
|
ST. DEV. |
2 |
6 |
8 |
|
N |
5 |
4 |
4 |
* Animal sacrificed for humane reasons on Day 3. Body weight: 161 gram.
MACROSCOPIC FINDINGS
ANIMAL |
ORGAN |
FINDING |
DAY OF DEATH |
MALES 2000 MG/KG |
|
|
|
1 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
2 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
3 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
4 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
5 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
FEMALES 2000 MG/KG |
|
|
|
6 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
7 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
8 |
|
No findings noted |
Killed in extremis Day 3 after treatment. |
9 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
10 |
|
No findings noted |
Scheduled necropsy Day 15 after treatment |
Applicant's summary and conclusion
- Interpretation of results:
- other: EU classification criteria not met
- Conclusions:
- The dermal LD50 value of Lowinox® 22IB46 in Wistar rats was established to exceed 2000 mg/kg body weight.
- Executive summary:
The objective of the study was to assess the systemic toxicity of the test item when administered to rats as a single dermal application. The results of the study allows for the test item to be ranked according to most classification systems. This study should provide a rational basis for risk assessment in man. The dermal route was selected, as it is a possible route of human exposure during manufacture, handling or use of the test item. The study complied to the following guidelines:
-Organization for Economic Co-operation and Development (OECD), OECD Guidelinesfor Testing of Chemicals, Section 4, Health Effects, No. 402, "Acute Dermal Toxicity",Paris, 1987.
-Commission Regulation (EC) No 440/2008 Part B: Methods for the Determination ofToxicity and other Health Effects; B.3: "Acute Toxicity (Dermal)". Official Journal of theEuropean Union No. L142, May 2008, including most recent amendments.
-United States Environmental Protection Agency (EPA). Health Effects Test Guidelines,OPPTS 870.1200, Acute Dermal Toxicity. Office of Prevention, Pesticides and ToxicItems (7101), EPA 712-C-98-192, August 1998.
-Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF), 12 Nousan,Notification No 8147, November 2000; including the most recent partial revisions.
One female animal was sacrificed for humane reasons on Day 3. No further mortality occurred.
Lethargy, tremors, flat- and hunched posture, lateral recumbency, rales, uncoordinated movements, shallow respiration, piloerection, chromodacryorrhoea (snout), hypersensitivity to touch and/or ptosis were noted for the animals of both sexes. The male animals had recovered from the symptoms by Day 4 and the females by Day 6. Additionally, one female animal showed lean appearance between Days 5 and 10. General erythema, erythema maculate and/or scabs were seen in the skin-area of the animals during the observation period. These local effects were considered not to have affected the conclusion of the study.
The changes noted in body weight gain in males were within the range expected for rats used in this type of study and were therefore considered not indicative of toxicity. The female animals showed body weight loss or reduced body weight gain between Days 1 and 8. At Day 15 the body weight of the animals were within the expected rage again.
No abnormalities were found at macroscopic post mortem examination of the animals.
The dermal LD50 value of Lowinox® 22IB46 in Wistar rats was established to exceed 2000 mg/kg body weight. Based on these results the following can be concluded:
-According to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2015) (including all amendments), Lowinox® 22IB46 should be classified as: may be harmful in contact with skin (Category 5) for acute toxicity by the dermal route;
-According to the Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures, Lowinox® 22IB46 does not have to be classified and has no obligatory labelling requirement for dermal toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.